[Impact of concurrent use of goserelin on the efficacy of neoadjuvant chemotherapy in young breast cancer patients].
For young breast cancer patients with clinical stages of ⅡA~ⅢC, there was no statistical difference in pCR rate and ORR whether or not using goserelin during NAC. However, it is still necessary to expand the sample size and carry out a longer follow-up to evaluate the effect of goserelin on the long-term survival of young patients.
Authors
- Lin Pei (ORCID: https://orcid.org/0000-0003-4904-199X)
- Miaoyu Liu
- Shu Wang (ORCID: https://orcid.org/0000-0003-0829-5694)
- Siyuan Wang (ORCID: https://orcid.org/0000-0002-8452-0083)
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-18
- DOI
- https://doi.org/10.19723/j.issn.1671-167x.2025.02.011
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article